Malignant Neoplasm of Breast유방의 악성신생물 (유방암)
| Classification codes | C50 (ICD-10) — C50.0 nipple, C50.1 central portion of breast, C50.2 upper-inner quadrant, C50.3 lower-inner quadrant, C50.4 upper-outer quadrant (most common), C50.5 lower-outer, C50.6 axillary tail, C50.8 overlapping, C50.9 unspecified |
| Synonyms | Breast cancer, invasive breast carcinoma, triple-negative breast cancer (TNBC), HER2-positive breast cancer, hormone receptor-positive breast cancer, ductal carcinoma in situ of the breast (DCIS) |
| Adult onset | Very high — the most common cancer in Korean women (excluding thyroid cancer); peaks at ages 45–54; frequency increases from the 30s |
| Special Copayment Reduction | V193 — 5 years from the date of cancer patient registration, copayment 5% |
| 1. History | Imhotep papyrus (2600 BC), Halsted radical mastectomy (1894), tamoxifen (1977), discovery of BRCA1/2 (1994/1995) |
| 2. Causes | BRCA1/2 mutations, estrogen exposure, age, obesity, alcohol, radiation, family history |
| 3. Genetics | BRCA1/2/PALB2/CHEK2/ATM/TP53/PIK3CA/HER2/CDH1; molecular subtypes (Luminal/HER2+/TNBC) |
| 4. Epidemiology | Most common cancer in Korean women (ASR 55.6); screening rate 70.6% in 2024; increasing early stage at diagnosis |
| 5. Pathophysiology | Estrogen-driven cell proliferation→DNA damage→multistep carcinogenesis; BRCA loss→homologous recombination deficiency |
| 6. Symptoms | Painless breast mass, nipple discharge, skin changes (peau d'orange), breast asymmetry |
| 7. Signs | Hard mass, axillary lymphadenopathy, skin fixation, nipple retraction |
| 8. Screening | National cancer screening mammography every 2 years (ages 40–69), combined ultrasound, criteria for BRCA genetic testing |
| 9. Diagnosis | Mammography/ultrasound/MRI/core needle biopsy/ER·PR·HER2·Ki-67/BRCA testing |
| 10. Treatment | Breast-conserving surgery/mastectomy+sentinel lymph node/chemotherapy/endocrine (tamoxifen·AI)/CDK4/6i/HER2-targeted/PARP inhibition/immunotherapy |
| 11. Prognosis | Korean 5-year survival rate for stage I–II >90%; prognostic differences by molecular subtype; TNBC poor |
| 12. Prevention | Breast self-examination, regular mammography, prophylactic surgery/chemoprevention for BRCA carriers |
| 13. References | Key references |
1. History
Breast cancer is one of the longest-described cancers in human history. The Egyptian Imhotep papyrus (about 2600 BC) contains a description of "bulging tumors of the breast (ulcer of the breast)" and records that there was no treatment for it. In ancient Greece, Hippocrates (BC 460–370) explained breast tumors as an excess of black bile, and Galen (130–200 AD) systematically described breast cancer and recommended surgery.
The milestone of modern breast cancer treatment is the Halsted radical mastectomy, introduced by William Stewart Halsted in 1894. This operation, which removes the breast, pectoralis major, pectoralis minor, and axillary lymph nodes, remained the standard until the mid-20th century. In the 1970s–1980s, NSABP (National Surgical Adjuvant Breast and Bowel Project) studies led by Bernard Fisher demonstrated that breast-conserving surgery achieves survival equivalent to radical mastectomy.
In the history of endocrine therapy, George Beatson first observed remission of breast cancer with oophorectomy in 1896, and the subsequent discovery of the estrogen receptor (ER) (Elwood Jensen, 1958) and the clinical application of tamoxifen (1970s) became the foundation of endocrine therapy for breast cancer. In genetics, the BRCA1 gene (Mary-Claire King) was discovered in 1994 and the BRCA2 gene in 1995, elucidating the molecular mechanism of hereditary breast cancer. Since the 2000s, HER2-targeted therapy, led by trastuzumab (FDA approval 1998), has been introduced and dramatically improved the prognosis of HER2-positive breast cancer. In Korea, since mammography was introduced into the National Cancer Screening Program in 2002, the screening rate had risen to 70.6% as of 2024.
2. Causes
Breast cancer arises from a complex interaction of genetic factors and environmental and lifestyle factors.
Genetic factors
- BRCA1/BRCA2 mutations: the most important cause of hereditary breast cancer. The lifetime breast cancer risk of BRCA1 mutation carriers is about 60–72%, and of BRCA2 carriers about 45–69%. In Korea, hereditary breast cancer is estimated to account for about 5–10% of all breast cancers.
- Other high-risk genes: TP53 (Li-Fraumeni), PTEN (Cowden), STK11 (Peutz-Jeghers), CDH1 (increased risk of lobular type), PALB2 (interacts with BRCA1)
- Moderate-risk genes: CHEK2, ATM mutations increase breast cancer risk 2–3 times.
Reproductive and endocrine factors
- Early age at menarche, late age at menopause (longer duration of estrogen exposure)
- Late age at first birth or nulliparity, no history of breastfeeding
- Postmenopausal hormone replacement therapy (estrogen+progestin combination)
- Long-term use of oral contraceptives (relative risk about 1.2)
Lifestyle factors
- Obesity: particularly postmenopausal obesity. The mechanism is increased conversion to estrogen in adipose tissue.
- Alcohol: alcohol intake increases breast cancer risk in a dose-dependent manner (relative risk about 1.46 with daily drinking).
- Radiation exposure: increased breast cancer risk after chest radiation therapy in the teens to 30s (Hodgkin lymphoma, etc.).
- Physical inactivity: increased physical activity is associated with reduced breast cancer risk.
3. Genetics
The breast cancer genome is highly heterogeneous, and treatment approaches differ by molecular subtype.
Major driver genes
| Gene | Type of alteration | Clinical significance |
| BRCA1/BRCA2 | Germline/somatic mutation | Homologous recombination deficiency (HRD); PARP inhibitor sensitivity |
| PALB2 | Germline mutation | Interacts with BRCA2; HRD; consider PARP inhibitors |
| PIK3CA | Somatic mutation (about 35%) | Common in ER+ breast cancer; target of alpelisib |
| HER2(ERBB2) | Amplification/overexpression (about 15–20%) | Target of trastuzumab, pertuzumab, T-DM1, T-DXd |
| TP53 | Mutation | Common in TNBC (about 80%); poor prognosis |
| CDH1(E-cadherin) | Mutation/loss | Specific to lobular breast cancer; associated with hereditary diffuse gastric cancer |
Molecular subtype classification
Breast cancer is classified into four main molecular subtypes according to gene expression patterns.
- Luminal A: ER+, PR+, HER2-, low Ki-67. Most common, with a favorable prognosis. Responds to endocrine therapy.
- Luminal B: ER+, variable PR, HER2- or HER2+, high Ki-67. Worse prognosis than Luminal A. Chemotherapy may be needed.
- HER2-enriched: ER-, PR-, HER2+. Responds to HER2-targeted therapy. Prognosis was poor in the past but has greatly improved with targeted therapy.
- Triple-negative (TNBC, Triple-Negative Breast Cancer): ER-, PR-, HER2-. About 15–20%. Worst prognosis. Chemotherapy is the mainstay; pembrolizumab is added if PD-L1-positive.
- Claudin-low: basal cell features, stem cell phenotype; poor prognosis.
Pharmacogenomics
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) have been established as the standard treatment for HR+/HER2- advanced breast cancer. PARP inhibitors (olaparib, talazoparib) have demonstrated efficacy in HR-/HER2- breast cancer with germline BRCA1/2 mutations (OlympiA trial). The concepts of HER2-low and HER2-ultralow have been introduced into clinical practice with the expanded indications of T-DXd (trastuzumab deruxtecan) (DESTINY-Breast06, 2024).
4. General epidemiology
Breast cancer is the most common cancer in Korean women excluding thyroid cancer; according to 2023 Korean cancer statistics, its age-standardized incidence rate (ASR) was 55.6 (per 100,000 population), ranking first among cancers in women. It is also the 5th leading cause of cancer death (ASR 5.5). Unlike in Western countries, the pattern of breast cancer incidence in Korea has shown a peak at ages 45–54 followed by a decline, but recently incidence has also been increasing in those aged 60 and older.
The Korean National Cancer Screening Program (KNCSP) introduced biennial mammography screening for women aged 40 and older in 2002, and the screening rate rose sharply from 38.4% in 2005 to 70.6% in 2024. As a result, the proportion of localized-stage (early) diagnoses increased from 60.3% in 2005 to 71.8% in 2023. The 5-year relative survival rate is 93.3% (Korea, 2017–2021), one of the highest in the world. Male breast cancer is very rare, accounting for less than about 1% of all breast cancers.
5. Pathophysiology
The pathogenesis of breast cancer varies by molecular subtype, and the best understood is the estrogen-driven carcinogenic pathway.
Estrogen-driven carcinogenesis (Luminal type)
Estrogen binds to the estrogen receptor (ER-α) and promotes proliferation of breast epithelial cells. During continuous cell proliferation and DNA replication, DNA damage from oxidative metabolites accumulates. As additional molecular events accumulate, such as PIK3CA mutations (PI3K pathway activation), CCND1 amplification (CDK4/6 hyperactivation), and ESR1 mutations (endocrine therapy resistance), the disease progresses to invasive breast cancer.
BRCA-related carcinogenesis
BRCA1/BRCA2 proteins play a key role in homologous recombination (HR) repair of DNA double-strand breaks. When loss of BRCA1/2 function causes homologous recombination deficiency (HRD), DNA damage cannot be repaired and genomic instability worsens. This leads mainly to ER- basal-like breast cancer and explains the high sensitivity to PARP inhibitors.
HER2 overexpression carcinogenesis
HER2 gene amplification and protein overexpression cause sustained activation of the PI3K/AKT/mTOR and RAS/MAPK pathways via HER2/HER3 heterodimers, promoting cell proliferation, survival, and metastasis.
6. Symptoms
Breast cancer is often asymptomatic in the early stage, and an increasing number of cases are found through screening.
Symptoms related to the primary breast tumor
- Breast mass: the most common symptom. Most are painless, hard, and have irregular margins. The absence of pain does not mean the mass is benign.
- Nipple discharge: bloody or serous nipple discharge. Attention is needed especially when the discharge is spontaneous from one breast and one duct.
- Skin changes: skin dimpling, orange-peel appearance (peau d'orange, dermal lymphatic invasion), redness, edema. Peau d'orange is a characteristic finding of inflammatory breast cancer.
- Nipple changes: nipple retraction, eczema of the nipple skin (nipple-areola eczema in Paget disease)
- Change in breast size or shape: breast asymmetry, change in the shape of one breast or part of a breast
Symptoms related to metastasis
- Axillary lymphadenopathy (lymph node metastasis)
- Bone metastasis: bone pain, pathologic fracture
- Liver metastasis: upper abdominal discomfort, jaundice
- Lung metastasis: cough, dyspnea
- Brain metastasis: headache, neurological symptoms
7. Signs
The main clinical signs suggestive of breast cancer on physical examination are as follows.
- Breast mass: a hard mass with irregular margins, fixed to surrounding tissue, and without tenderness suggests malignancy. Attachment to the skin or fascia indicates a high likelihood of malignancy.
- Dimpling: skin dimpling due to involvement of Cooper's ligaments
- Peau d'orange: skin edema and enlarged pores due to tumor spread in the dermal lymphatics
- Nipple retraction: the nipple is pulled inward due to duct contraction caused by the tumor
- Axillary lymphadenopathy: hard, fixed axillary lymph nodes; with malignant lymph node metastasis, a fused mass of lymph nodes (matted nodes) is particularly palpable
- Signs of inflammatory breast cancer: redness, warmth, edema, and tenderness of the entire breast; confirmed by skin biopsy
- Elevated tumor markers such as CA 15-3 and CEA may suggest metastatic disease but are not used for diagnostic purposes.
8. Screening
Korean National Cancer Screening Program
The standard of Korean national cancer screening is mammography every 2 years for women aged 40–69. It is provided free of charge through the National Health Insurance Service. Mammography is known to increase the proportion of breast cancers detected at an early stage and to reduce breast cancer mortality by about 15–20%.
Additional test methods
- Breast ultrasound: more sensitive than mammography alone in dense breasts. About 35–40% of Korean women have dense breasts, in which case combined mammography and ultrasound is recommended.
- Breast MRI: annual breast MRI is recommended for BRCA1/2 mutation carriers, those with a strong family history, and high-risk groups. It is highly sensitive but has low specificity, which may increase unnecessary biopsies.
- Breast self-examination (BSE): regular monthly self-examination is recommended as a complement to clinical breast examination (CBE) by a physician.
Criteria for BRCA genetic testing
BRCA1/BRCA2 genetic testing is recommended if one or more of the following apply: a strong family history of breast or ovarian cancer, breast cancer diagnosed before age 40, triple-negative breast cancer (before age 60), bilateral breast cancer, male breast cancer, or simultaneous diagnosis of breast and ovarian cancer. In Korea, the criteria for BRCA testing covered by National Health Insurance are specified.
9. Diagnosis
The diagnosis of breast cancer is made by a triple approach of radiology, histopathology, and molecular pathology.
Imaging tests
- Mammography: the primary screening and diagnostic tool. The need for further testing is decided according to the BI-RADS (Breast Imaging-Reporting and Data System) classification (1–6).
- Breast ultrasound: evaluates the characteristics of the mass (cystic/solid), blood flow, and surrounding lymph nodes.
- Breast MRI: useful for evaluating tumor extent (multifocal/multicentric lesions), examining the contralateral breast, and assessing response to neoadjuvant chemotherapy.
- PET-CT: used to evaluate distant metastasis.
Histopathological diagnosis
- Core needle biopsy: the standard method for confirming breast cancer. Performed under ultrasound or stereotactic guidance.
- Immunohistochemistry (IHC): ER, PR, HER2, Ki-67 testing is essential for molecular subtype classification and treatment decisions. HER2 IHC 2+ is confirmed by FISH/ISH.
- Oncotype DX, MammaPrint: multigene expression tests (genomic assays) used to determine the need for chemotherapy in early ER+/HER2- breast cancer.
Staging
The AJCC 8th edition TNM staging system is used, and in addition to tumor size (T), lymph node status (N), and distant metastasis (M), a Prognostic Stage integrating prognostic factors such as ER/PR/HER2, tumor grade, and the Oncotype DX recurrence score is used.
10. Treatment
The standard for breast cancer treatment is a highly personalized multidisciplinary approach according to stage, molecular subtype, and patient characteristics.
Surgical treatment
- Breast-conserving surgery (BCS): the standard surgery for stage 1–2 breast cancer. Adjuvant radiation therapy is essential. Tumor resection + radiation therapy shows survival equivalent to total mastectomy.
- Total mastectomy: for multifocal lesions, BRCA mutations, contraindications to radiation therapy, and the like. Prophylactic contralateral mastectomy may be performed at the same time.
- Sentinel lymph node biopsy (SLNB): the standard for clinically node-negative cases. If there is no metastasis in the sentinel lymph node, complete axillary lymph node dissection (ALND) can be omitted.
Adjuvant chemotherapy
- AC (doxorubicin+cyclophosphamide) → a taxane (paclitaxel or docetaxel) is the backbone of standard adjuvant therapy.
- In TNBC, the addition of carboplatin and combination immunotherapy with pembrolizumab (KEYNOTE-522) have been introduced as standard.
Endocrine therapy
- Tamoxifen: the standard for premenopausal ER+ breast cancer. Given for 5–10 years.
- Aromatase inhibitors (AI; letrozole, anastrozole, exemestane): the standard for postmenopausal ER+ breast cancer. Superior efficacy to tamoxifen.
- CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib): in combination with an AI, significantly improve progression-free and overall survival in HR+/HER2- advanced breast cancer. Currently the standard first-line treatment.
HER2-targeted therapy
- Trastuzumab (Herceptin): the basic targeted agent for HER2+ breast cancer.
- Pertuzumab: in combination with trastuzumab, for pre- and postoperative adjuvant therapy and first-line treatment of metastatic disease.
- T-DM1 (Trastuzumab emtansine): adjuvant therapy for residual disease after neoadjuvant chemotherapy in HER2+ early breast cancer.
- T-DXd (Trastuzumab deruxtecan): second-line for HER2+ metastatic breast cancer; efficacy also demonstrated in HER2-low/ultralow breast cancer (DESTINY-Breast06, 2024).
PARP inhibitors and immunotherapy
- Olaparib: adjuvant therapy for high-risk HER2- early breast cancer with germline BRCA1/2 mutations (OlympiA trial).
- Pembrolizumab: neoadjuvant-adjuvant therapy for high-risk early TNBC (KEYNOTE-522); first-line treatment of metastatic TNBC (PD-L1 CPS≥10).
11. Prognosis
| Stage / subtype | Korean 5-year survival rate |
| Overall 5-year relative survival rate (Korea 2017-2021) | 93.3% |
| Stage I | >97% |
| Stage II | About 88–92% |
| Stage III | About 70–80% |
| Stage IV (metastatic) | About 29% |
| Luminal A | Most favorable; 10-year survival rate 80–90% |
| HER2-positive (trastuzumab era) | Greatly improved; 5-year survival rate about 85–90% (early) |
| Triple-negative (TNBC) | 5-year survival rate about 77% (early); worst when metastatic |
Molecular subtype has the most important effect on prognosis, and Ki-67, tumor grade, lymph node status, and tumor size are also important prognostic factors. The higher the Oncotype DX Recurrence Score, the greater the benefit of chemotherapy and the worse the prognosis. With the recent introduction of CDK4/6 inhibitors, T-DXd, PARP inhibitors, and others, survival in advanced breast cancer continues to improve.
12. Prevention
Participation in screening
- Participate regularly in biennial mammography screening starting at age 40. For dense breasts, consider adding breast ultrasound.
- Perform a monthly breast self-examination and visit a medical institution immediately if any abnormality is found.
Lifestyle modification
- Maintain a healthy weight after menopause (BMI under 25): obesity is a risk factor for postmenopausal breast cancer.
- Moderate drinking or abstinence from alcohol: there is a dose-dependent association with breast cancer risk.
- Regular physical activity: moderate exercise of 150 minutes or more per week reduces breast cancer risk by about 20–30%.
- Breastfeeding: associated with reduced breast cancer risk.
Risk-reduction strategies for BRCA carriers
- Risk-reducing mastectomy: reduces breast cancer risk by about 90% or more in BRCA1/2 mutation carriers.
- Chemoprevention: tamoxifen, raloxifene, AIs, and others are effective in reducing breast cancer risk in high-risk groups.
- BRCA mutation carriers begin surveillance with annual breast MRI combined with mammography from age 25.
13. References
- Cancer Statistics in Korea 2023. Cancer Res Treat. 2025. PMC13093029.
- Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality. NPJ Breast Cancer. 2021. PMC8238931.
- Trends in Cancer-Screening Rates in Korea. Cancer Res Treat. 2024.
- KEYNOTE-522: Pembrolizumab + chemo neoadjuvant/adjuvant for early TNBC. NEJM. 2022.
- OlympiA: Olaparib adjuvant for high-risk HER2-negative germline BRCA breast cancer. NEJM. 2021.
- DESTINY-Breast06: T-DXd in HER2-low/ultralow metastatic BC. NEJM. 2024.
- Diagnosis and treatment of HER2-positive breast cancer. Korean J Med. 2025;100(2):81.
- Palbociclib as first-in-class CDK4/CDK6 inhibitor for HR+/HER2- advanced BC. PMC4534142.
- Korean Breast Cancer Society. Breast cancer clinical practice recommendations 2023. 2023.
- National Cancer Information Center. Breast cancer. 2024.